Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate 11:44:52 2024-05-23 am EDT 5-day change 1st Jan Change
27.66 EUR -2.61% Intraday chart for Bayer AG -3.33% -17.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BAYER AG : JP Morgan reiterates its Neutral rating ZD
BAYER AG : UBS remains Neutral ZD
IQ-AI Unit Delivers Software to Insel Gruppe MT
Bayer: elinzanetant data presented at congress CF
Bayer’s Menopause Drug Reduces Hot Flashes in Late-stage Studies MT
Ag inputs sales seen at good level in the US, not as good in South America RE
Bayer to present new data at ASCO CF
Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer CI
BAYER AG : Barclays remains Neutral ZD
Chemical industry sees first rays of hope and becomes more confident for 2024 DP
BAYER AG : UBS remains Neutral ZD
Bayer Launches First-in-Human Study of Prostate Cancer Drug Candidate MT
BAYER : As soft as anticipated Alphavalue
Global markets live: Apple, Sony, Vodafone, Booking, Walmart... Our Logo
Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update DJ
Transcript : Bayer Aktiengesellschaft, Q1 2024 Earnings Call, May 14, 2024
Jefferies rates Bayer a 'Hold' - Target 29 euros DP
BAYER AG : Gets a Neutral rating from JP Morgan ZD
Deutsche Bank Research rates Bayer a 'Hold' - Target 29 euros DP
BAYER AG : Deutsche Bank reaffirms its Neutral rating ZD
CAC40: little movement on the eve of US inflation CF
BAYER AG : Gets a Neutral rating from UBS ZD
Bayer stagnates after good run - headwind from exchange rates DP
Bayer: core EPS down 4% in Q1 CF
CAC 40: caution ahead of a series of indicators CF
Chart Bayer AG
More charts
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
28.4 EUR
Average target price
36.9 EUR
Spread / Average Target
+29.97%
Consensus
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. News Bayer AG
  5. Bayer’s Investigational Gene Therapy for Heart Failure Gets US FDA Fast Track Designation